Iovance Biotherapeutics (IOVA)

• Market cap: $1.15B
• 1 day: -7.85%
• 5 days: -4.86%
• 1 month: -34.08%
• 3 months: -55.04%
• 6 months: -65.96%
• Year to date: -54.81%
• 1 year: -76.10%
• 5 years: -86.00%
• 10 years: -73.17%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Employees: 838

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

71% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 34

20% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 83

6% more funds holding

Funds holding: 283 [Q3] → 299 (+16) [Q4]

1.37% more ownership

Funds ownership: 77.86% [Q3] → 79.23% (+1.37%) [Q4]

20% less capital invested

Capital invested by funds: $2.22B [Q3] → $1.79B (-$434M) [Q4]

21% less call options, than puts

Call options by funds: $28.9M | Put options by funds: $36.4M

22% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 70% upside
• Avg. target: $20 478% upside
• High target: $32 809% upside

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

Truist Securities Asthika Goonewardene 28% 1-year accuracy 7 / 25 met price target	326% upside $15	Buy Maintained	3 Mar 2025
Goldman Sachs Andrea Tan 50% 1-year accuracy 4 / 8 met price target	440% upside $19	Buy Maintained	3 Mar 2025
Chardan Capital Geulah Livshits 14% 1-year accuracy 8 / 59 met price target	752% upside $30	Buy Maintained	3 Mar 2025
Baird Michael Ulz 32% 1-year accuracy 6 / 19 met price target	468% upside $20	Outperform Maintained	28 Feb 2025
Piper Sandler Joseph Catanzaro 33% 1-year accuracy 10 / 30 met price target	70% upside $6	Neutral Maintained	28 Feb 2025